Compounds > rivastigmine
Page last updated: 2024-08-16

rivastigmine and Atrophy

rivastigmine has been researched along with Atrophy in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Junne, F; Krüger, R; Sammet, I; Schäffeler, N; Teufel, M; Wettach, I; Zipfel, S1
de Brito-Marques, PR; de Mello, RV; Montenegro, L1
Charles, HC; Farlow, MR; He, Y; Lane, R; Tekin, S; Xu, J1
Pelgrim, E; Scheltens, P; Verhey, FR; Visser, PJ1

Other Studies

4 other study(ies) available for rivastigmine and Atrophy

ArticleYear
[Somatoform disorder or neurological syndrome? Complex mental and movement disorder and autonomic dysfunction in a 65-year-old patient - Case 1/2011].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:3

    Topics: Adaptation, Psychological; Aged; Atrophy; Cholinesterase Inhibitors; Combined Modality Therapy; Cough; Diagnosis, Differential; Exercise Therapy; Female; Humans; Magnetic Resonance Imaging; Mesencephalon; Neurologic Examination; Occupational Therapy; Phenylcarbamates; Psychotherapy; Rivastigmine; Sick Role; Somatoform Disorders; Supranuclear Palsy, Progressive; Syncope

2011
Nightmares without atonia as an early symptom of diffuse Lewy bodies disease.
    Arquivos de neuro-psiquiatria, 2003, Volume: 61, Issue:4

    Topics: Aged; Atrophy; Carbamates; Cholinesterase Inhibitors; Dreams; Fatal Outcome; Humans; Immunohistochemistry; Lewy Body Disease; Magnetic Resonance Spectroscopy; Male; Neurons; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Substantia Nigra; Tomography, X-Ray Computed

2003
Impact of APOE in mild cognitive impairment.
    Neurology, 2004, Nov-23, Volume: 63, Issue:10

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Atrophy; Cognition Disorders; Female; Genetic Predisposition to Disease; Genotype; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine

2004
Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Dementia and geriatric cognitive disorders, 2005, Volume: 19, Issue:2-3

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Atrophy; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genetics; Genotype; Humans; Magnetic Resonance Imaging; Male; Mental Status Schedule; Netherlands; Neuroprotective Agents; Phenylcarbamates; Prognosis; Psychometrics; Rivastigmine; Temporal Lobe; Treatment Outcome

2005